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Changes in Choroidal Thickness 
follow the RNFL Changes in Leber’s 
Hereditary Optic Neuropathy
Enrico Borrelli1, Giacinto Triolo1, Maria Lucia Cascavilla1, Chiara La Morgia2,3, 
Giovanni Rizzo2,3, Giacomo Savini4, Nicole Balducci5, Paolo Nucci6, Rosa Giglio1, 
Fatemeh Darvizeh1, Vincenzo Parisi4, Francesco Bandello1, Alfredo A. Sadun7, Valerio Carelli2,3 
& Piero Barboni1,5
Leber’s hereditary optic neuropathy (LHON) is typically characterized by vascular alterations in the 
acute phase. The aim of this study was to evaluate choroidal changes occurring in asymptomatic, acute 
and chronic stages of LHON. We enrolled 49 patients with LHON, 19 with Dominant Optic Atrophy 
(DOA) and 22 healthy controls. Spectral Domain-Optical Coherence Tomography (SD-OCT) scans of 
macular and peripapillary regions were performed in all subjects, to evaluate macular and peripapillary 
choroidal thickness, and retinal nerve fiber layer (RNFL) thicknes. Macular and peripapillary choroidal 
thicknesses were significantly increased in the acute LHON stage. On the contrary, macular choroidal 
thickness was significantly reduced in the chronic stage. Furthermore, peripapillary choroidal thickness 
was decreased in chronic LHON and in DOA. Both RNFL and choroid had the same trend (increased 
thickness, followed by thinning), but RNFL changes preceded those affecting the choroid. In conclusion, 
our study quantitatively demonstrated the involvement of the choroid in LHON pathology. The increase 
in choroidal thickness is a feature of the LHON acute stage, which follows the thickening of RNFL. 
Conversely, thinning of the choroid is the common outcome in chronic LHON and in DOA.
Optic nerve damage has been recognized as a frequent feature of mitochondrial diseases. Leber’s Hereditary 
Optic Neuropathy (LHON) and Dominant Optic Atrophy (DOA) are both caused by mitochondrial dysfunction 
and are characterized by tissue selectivity, usually limited to damaging the retinal ganglion cells (RGCs) and their 
axons in the optic nerve1–4.
LHON is a maternally inherited genetic disorder caused by mitochondrial DNA (mtDNA) point mutations 
affecting different subunits of complex I and leading to dysfunction in the mitochondrial respiratory chain. The 
three most frequent pathogenic mutations are at nucleotide positions 11778/ND4, 3460/ND1, and 14484/ND6. 
Clinically, LHON is characterized by simultaneous or sequential acute loss of visual acuity with bilateral central 
scotomas that occur most frequently in young men2,4. The smaller-caliber fibers of the papillomacular bundle are 
selectively lost in early stages of the pathologic process5–7. Fiber loss eventually progresses, as a wave, to ultimately 
involve the entire optic nerve and manifest as optic atrophy8.
Asymptomatic carriers of the mtDNA LHON mutations and especially carriers about to convert before the 
acute phase of the disease often show classical ophthalmoscopic changes: circumpapillary telangiectatic microa-
ngiopathy, small vessel tortuosity, and swelling of the RNFL inferior-temporally8–10. When the disease becomes 
symptomatic and the patient experiences loss of central vision, there may be a concomitant increase in microa-
ngiopathy accompanied by swelling of the superior and inferior fiber arcades and rapid loss of the papillomac-
ular bundle8,11. Over a period of weeks to months, the microangiopathy and nerve fiber swelling decrease and 
unmask extensive optic disc atrophy. By 6 months after onset, optic atrophy is usually pronounced and visual loss 
stabilizes. The pathophysiologic mechanisms of disease at conversion remain unclear with several hypotheses 
having been proposed that usually involve increased reactive oxygen species (ROS) accumulation, reduced ATP 
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availability, and stasis of axoplasmic flow due to impaired axonal transport. Less understood however, are the 
vascular changes as reflected by the telangiectasias. Thus, the question arises, is there a primary micro-vascular 
disorder in LHON?
DOA, at difference with LHON, is a neurodegenerative disorder associated with dominant mutations in the 
nuclear gene OPA1, which encodes a dynamin-related GTPase targeted to mitochondria and involved in the 
fusion of mitochondrial inner membrains4,12–14. Clinically, DOA is characterized by a slowly progressive bilateral 
visual loss, starting in childhood and ultimately leading to various degrees of optic atrophy15,16. Both the visual 
loss and the optic atrophy are not usually as severe in DOA as in LHON1,2.
Advances in ocular imaging, with the introduction of the spectral domain optical coherence tomography 
(SD-OCT) have enabled clinicians to visualize in detail retinal and choroidal structures, the latter using the 
enhanced depth imaging (EDI) technique17. Recently, SD-OCT has been instrumental in the qualitative and 
quantitative assessment of funduscopic changes over the natural history of LHON8,18,19. Nevertheless, OCT stud-
ies have been focused on measuring RNFL and RGC thickness, whereas the vascular changes remained neglected 
and poorly evaluated. A few studies have shown vascular changes occurring in inflammatory papillitis20,21, nev-
ertheless none tested the choroidal thickness in mitochondrial optic neuropathies. The aim of this study is to fill 
this gap by investigating choroidal thickness in asymptomatic, acute and chronic stages of LHON. Moreover, we 
compared choroidal thickness in two mitochondrial diseases causing optic atrophy, LHON in its chronic stage 
and DOA.
Methods
Subjects. Forty-nine consecutive LHON patients (98 eyes) were recruited for the study, all at the University 
Eye Clinic of San Raffaele Hospital between September 2012 and June 2015. All participants gave their informed 
consent according to the Declaration of Helsinki and the study was approved by the internal review board at the 
University Eye Clinic of San Raffaele Hospital, Milan. Moreover, all the subjects were tested in accordance with 
relevant guidelines and regulations.
All patients included in the present study had a molecularly confirmed diagnosis of LHON with an mtDNA 
primary mutation. Both eyes of all patients were considered for the analysis. We divided LHON eyes into 3 
groups: affected eyes during the acute phase (A-LHON), when the disease onset was less then 6 months before; 
affected eyes during the chronic phase (C-LHON), when the disease onset was more than 1 year and asympto-
matic mutation carriers (LHON carriers). Two patients were classified as ‘dynamic’ in the study groups because 
they were experiencing the dynamic anatomical changes characterizing this stage of the disease (between 6 
months and 1 year after onset).
Moreover, nineteen consecutive patients (38 eyes) affected by DOA were enrolled for the present study. All 
these patients had a diagnosis molecularly proved with an OPA1 pathogenic mutation.
All subjects had an extensive ophthalmologic examination, including best-corrected visual acuity measure-
ment, slit lamp biomicroscopy, intraocular pressure measurement, indirect ophthalmoscopy, and optic nerve 
head photography. Exclusion criteria were the presence of any retinal pathology and/or optic nerve disease other 
than either LHON or DOA, spherical and/or cylindrical refractive errors higher than 3 and 2 diopters respec-
tively, systemic conditions that may affect the vascular system (e.g. autoimmune condition, diabetes, and uncon-
trolled systemic hypertension).
Controls (22 subjects, 44 eyes) were healthy subjects analyzed during a routine ophthalmological examina-
tion. Inclusion criteria were: best corrected visual acuity better than 20/25, refractive errors lower than 3 diop-
ters of sphere and 2 diopters of cylinder, normal intraocular pressure (< 18 mm Hg), normal appearance of the 
optic disc, normal visual field (the latter was examined with a SITA 24-2 standard test in all subjects using the 
Humphrey VF analyzer, HFA II 750-4.1 2005, Carl Zeiss Meditec Inc, USA), no significant ocular disease found 
by routine ophthalmological examination, no history of glaucoma in the family and/or systemic diseases with 
possible ocular involvement, such as diabetes. Controls were matched with patients for age and refractive error 
because these factors have been shown to influence OCT measurements22,23. Moreover, because it has been shown 
that cigarette smoking leading to a significant increase in choroidal thickness up to 1 h after24, all the subjects had 
not smoked the hour before the examination. Finally, in order to avoid circadian choroidal changes that could 
influence our results25, all the tests were done during the morning.
Instrumentation and procedures. Enhanced depth imaging-optical coherence tomography. SD-OCT 
scans of macular and peripapillary regions were performed using the Heidelberg Spectralis (version 1.7.0.0, 
Heidelberg Engineering, Heidelberg, Germany). The images were obtained by using enhanced depth imaging, 
which places the focus more posterior than would normally be done during standard retinal SD-OCT imaging, in 
order to improve the choroidal resolution17. Two 9-mm high-quality line scans through the fovea (one horizontal 
and one vertical) were obtained for each eye; the peripapillary region was scanned using a 360°, 3.4 mm diameter 
circle scan that was centered on the optic disc. The images were shown and measured with the Heidelberg Eye 
Explorer software. The choroid was measured in a masked fashion by a trained investigator (E.B.), after pupil dila-
tion and in similar lighting and in the morning, from the outer portion of the hyper-reflective line corresponding 
to the retinal pigment epithelium (RPE) to the inner surface of the sclera. Macular measurements of the choroid 
thickness were made in the sub-foveal (SF) location and at 750 μm intervals from the fovea up to 1.5 mm nasal, 
1.5 mm temporal, 1.5 mm superior, and 1.5 mm inferior from the center of the fovea [Fig. 1]. The peripapillary 
choroidal thickness was measured at four points, each point being at 90° from the previous and consecutively, in 
order to investigate the temporal, superior, nasal and inferior peripapillary choroid thickness respectively [Fig. 1]. 
Furthermore, peripapillary RNFL thickness measurements were obtained by the same circle scan.
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Statistical analysis. Statistical calculations were performed using Statistical Package for Social 
Sciences (version 20.0. SPSS Inc. Chicago. IL. USA). To detect departures from normality distribution, the 
Kolmogorov-Smirnov test was performed for all variables. All quantitative variables were presented as mean 
and standard deviation (SD) in the results and in the tables. Parameters were compared by one-way analysis 
of covariance (ANCOVA), introducing sex and age as covariates, followed by Bonferroni post hoc test for pair 
wise comparisons. Pearson’s correlation was carried out among disease duration, best-corrected visual acuity, 
choroidal thickness and RNFL thickness measurements. In the correlation analysis, the A-LHON and C-LHON 
patients were grouped. Moreover, a regression analysis was focused on patients in the firsts 12 months from 
onset, including RNFL (average and temporal) and choroidal (average and temporal nerve and average and nasal 
macular) measurements.
The chosen level of statistical significance was p < 0.05.
Results
Demographic data of the investigated samples. Table 1 shows the demographic data of patients and 
healthy controls. Two eyes of 2 C-LHON patients had to be excluded from the analysis due to the poor quality of 
the scans.
Choroidal and RNFL analyses. Table 2 separately compares A-LHON, LHON carriers and healthy sub-
jects. Both macular and nerve choroidal thicknesses were significantly increased in A-LHON patients as com-
pared with control group, except in nasal and inferior nerve measurements. The LHON carrier group showed an 
increased choroidal thickness that reached statistical significance only in the average and in the inferior nerve 
Figure 1. (Top Figure) Representative horizontal 9-mm high-quality line scan through the fovea, from a 
healthy subject (control group). The choroid was measured from the outer portion of the hyperreflective line 
corresponding to the retinal pigment epithelium to the inner surface of the sclera. These measurements were 
made of the sub-foveal choroid and at 750 μ m intervals from the fovea to 1.5 mm nasal, 1.5 mm temporal, 
1.5 mm superior, and 1.5 mm inferior from the center of the fovea. (Bottom Figure) Representative 360°, 
3.4 mm diameter circle scan centered on the optic disc, from a healthy subject (control group). The choroid was 
measured from the outer portion of the hyperreflective line corresponding to the retinal pigment epithelium 
to the inner surface of the sclera. These measurements were made of four points: each point is far from the 
previous and the consecutive 90°.
Chronic 
LHON Acute LHON
‘Dynamic’ 
LHON
LHON 
Carriers DOA patients
Healthy 
controls
Number of participants 
(number of eyes analyzed) 20 (38) 6 (12) 2 (4) 21 (42) 19 (38) 22 (44)
Gender (number of males) 16 5 2 10 13 14
Mutation carried, number of patients (number of eyes analyzed)
11778/ND4 13 (24) 6 (12) 2 (4) 15 (30) — —
3460/ND1 5 (10) 0 (0) 0 (0) 4 (8) — —
14484/ND6 2 (4) 0 (0) 0 (0) 2 (4) — —
OPA1 H-mutation — — — — 9 (18) —
OPA1 M-mutation — — — — 10 (20) —
Number of smokers 2 3 0 2 3
Age, years 36.0 ± 10.0 31.5 ± 12.1 36.0 ± 4.2 36.7 ± 13.3 37.5 ± 12.9 39.7 ± 10.1
Disease duration, years 11.8 ± 13.8 0.1 ± 0.1 0.7 ± 0.2 — — —
Visual acuity, decimals 0.11 ± 0.15 0.29 ± 0.43 0.04 ± 0.02 1.00 ± 0.00 0.36 ± 0.23 1.00 ± 0.00
Table 1.  Study participants’ demographic and clinical features. LHON: Leber Hereditary Optic Neuropathy; 
DOA: Dominant Optic Atrophy; H-mutation: OPA1 haploinsufficiency mutation; M-mutation: OPA1 
missense mutation. Data are showed as mean ± SD.
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choroidal thicknesses, as compared with the control group. Moreover, A-LHON patients compared with carriers 
demonstrated a significant thickening of macular choroidal measurements (excluding the 1500 μ m inferior one). 
Peri-optic nerve choroidal thickness measurements were increased, reaching significance only in the temporal 
sector, differently from comparable thickness in the inferior sectors.
Table 3 separately compares C-LHON, DOA and healthy subjects. Macular choroidal thickness was signifi-
cantly reduced in C-LHON patients (in which thinning failed to reach statistical significance only in the 1500 μ m 
nasal and in the 1500 μ m inferior measurements) as compared with control group. Reduction in peri-optic nerve 
choroidal thickness between C-LHON patients and healthy subjects failed to reach statistical significance, except 
for the inferior measurement that had comparable thickness. DOA patients had a significantly thinner macular 
choroid in all measurements as compared with controls and a reduction in peri-optic nerve choroidal thickness 
measurements failed to reach statistical significance. Furthermore, no difference was found in choroidal thickness 
between C-LHON and DOA [Table 3].
RNFL thickness comparisons among A-LHON, LHON carriers, C-LHON, DOA and healthy subjects are 
shown in Tables 4 and 5. In A-LHON patients RNFL thickness was significantly higher in average, superior and 
inferior measurements compared to both controls and carrier groups, whereas temporal thickness was similar 
when compared with controls and reduced when compared with carriers [Table 4]. In carriers, RNFL thickness 
was higher in average, temporal and inferior measurements in comparison to controls.
RNFL thickness was significantly thinner in both C-LHON and DOA groups, as compared with controls. 
Finally, RNFL was significantly thinner in the C-LHON group as compared with DOA (except for the temporal 
measurement) [Table 5].
Looking at the RNFL and choroid data simultaneously, it appeared that average measurements of both struc-
tures progressively increased from healthy subjects to LHON carriers and to A-LHON, followed by a progressive 
reduction in chronic states (Fig. 2, left panel). However, focusing on the papillomacular region of LHON patients, 
temporal RNFL thickness tended to decrease already in the acute phase, while peri-optic nerve choroid temporal 
and macular choroid nasal were clearly thicker (Fig. 2, right panel). Moreover, the choroidal thickening in the 
acute stage was more evident on temporal peri-optic nerve and nasal macular than in the temporal macular and 
average measurements [Fig. 2]. A summary of these results is shown in Fig. 3, which emphasizes the timing of 
choroidal and RNFL thickness changes in the different stages of LHON [Fig. 3].
A sub-analysis of different mutations in both LHON (stratifying the three primary mutations) and DOA (hap-
loinsufficiency vs missense) was also performed, failing to evidence any difference (not shown).
Correlations. Pearson test showed that LHON disease duration was inversely correlated with the inferior, 
nasal and temporal macular choroidal thickness measurements. Moreover, we found that average macular cho-
roidal thickness and average RNFL thickness, as well as average peri-optic nerve choroidal thickness and aver-
age RNFL thickness, were directly correlated (R2 = 0.627 and p < 0.0001, R2 = 0.369 and p = 0.013, respectively). 
Finally, a direct correlation was found between average macular choroidal and average nerve choroidal thick-
nesses (R2 = 0.576 and p < 0.0001).
Scatters plots in Fig. 4 show the relationship between disease duration in the first 12 months and average 
measurements of RNFL, nerve and macular choroid, and measurements corresponding to the papillomacular 
bundle region, in particular RNFL-T, nerve choroid temporal and macular choroid nasal. The best-fit relationship 
Acute 
LHON 
patients
Carrier 
LHON 
patients
Control 
group
Acute LHON 
patients vs 
Control group
Carrier LHON 
patients vs 
Control group
Acute LHON 
patients vs Carrier 
LHON patients
Average macular choroidal thickness (μ m) 403.4 ± 68.2 334.0 ± 81.6 309.5 ± 38.2 p < 0.0001** p = 0.255 p = 0.004**
Macular choroidal SF thickness (μ m) 425.6 ± 79.3 349.0 ± 90.1 344.1 ± 49.1 p = 0.003** p = 1.0 p = 0.006**
Macular choroidal 1500 mμ N thickness (μ m) 366.3 ± 95.9 295.3 ± 97.0 256.6 ± 59.2 p < 0.0001** p = 0.105 p = 0.030*
Macular choroidal 750 mμ N thickness (μ m) 406.9 ± 84.8 325.4 ± 90.7 309.2 ± 57.4 p = 0.001** p = 1.0 p = 0.005**
Macular choroidal 1500 mμ S thickness (μ m) 413.5 ± 70.4 344.7 ± 89.1 317.6 ± 42.9 p < 0.0001** p = 0.240 p = 0.014*
Macular choroidal 750 mμ S thickness (μ m) 428.9 ± 62.4 350.8 ± 91.2 318.2 ± 44.2 p < 0.0001** p = 0.113 p = 0.005**
Macular choroidal 1500 mμ T thickness (μ m) 376.5 ± 59.7 323.7 ± 74.7 300.1 ± 51.3 p = 0.001** p = 0.284 p = 0.039*
Macular choroidal 750 mμ T thickness (μ m) 398.3 ± 66.4 333.9 ± 81.9 322.3 ± 44.3 p = 0.002** p = 1.0 p = 0.011*
Macular choroidal 1500 mμ I thickness (μ m) 389.6 ± 85.5 338.5 ± 77.9 303.9 ± 40.3 p = 0.001** p = 0.051 p = 0.068
Macular choroidal 750 mμ I thickness (μ m) 402.1 ± 73.0 337.9 ± 83.9 313.4 ± 43.7 p = 0.001** p = 0.303 p = 0.018*
Average nerve choroidal thickness (μ m) 225.4 ± 64.2 197.3 ± 52.8 167.9 ± 37.5 p = 0.002** p = 0.038* p = 0.263
Nerve choroidal T thickness (μ m) 277.4 ± 78.2 206.0 ± 75.4 180.1 ± 37.9 p < 0.0001** p = 0.286 p = 0.003**
Nerve choroidal S thickness (μ m) 244.2 ± 67.1 214.3 ± 59.4 182.3 ± 48.2 p = 0.005** p = 0.054 p = 0.335
Nerve choroidal N thickness (μ m) 206.9 ± 56.1 196.5 ± 50.8 175.2 ± 51.3 p = 0.216 p = 0.253 p = 1.0
Nerve choroidal I thickness (μ m) 172.9 ± 80.2 172.6 ± 52.8 133.3 ± 41.0 p = 0.089 p = 0.007** p = 1.0
Table 2.  Comparison of macular and nerve choroidal thickness between LHON patients and the control 
group. LHON: Leber Hereditary Optic Neuropathy; SF: sub-foveal; T: temporal quadrant; S: superior quadrant; 
N: nasal quadrant; I: inferior quadrant. Data are showed as mean ± SD. Values were compared by means of one-
way analysis of covariance (ANCOVA), followed by Bonferroni post hoc test. Gender was used as covariate in 
the analysis. *< 0.05, **< 0.01.
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for all plots was using a cubic regression model, which showed increased thickness, which was followed by thin-
ning until an apparent plateau [Fig. 4]. The plots show that in the acute stage, thickening and subsequent thinning 
of RNFL start earlier compared with peri-optic nerve and macular choroids. This is more evident in the papil-
lomacular region, where the temporal RNFL thinning is already evident when both temporal nerve and nasal 
macular choroidal thickening starts [Fig. 4]. After 4–5 months following disease onset, the macular and peri-optic 
nerve choroidal thinning starts but remains thicker than normal until 12 months, also in the papillomacular 
region [Fig. 4].
Finally, we failed to find any correlation between choroidal thickness and best corrected visual acuity.
Discussion
In the present study, we evaluated macular and peripapillary choroidal thickness in LHON patients. Overall, 
we found that both macular and peripapillary choroidal thicknesses increased in the acute stage. Moreover, we 
showed a decreased macular choroidal thickness in the chronic stage. Most importantly, we have evidence that 
the increased thickness of axons preceded the changes of choroidal thickness, suggesting that one event may lead 
to the other.
It has always been recognized that asymptomatic and acute stages of LHON were characterized by vascu-
lar changes, such as peripapillary microangiopathy and vascular telangiectasias10,11. These signs are more pro-
nounced in the acute phase and, once vision loss stabilizes, the vascular abnormalities fade. Nevertheless, to 
the best of our knowledge, there is no study that serially evaluated the vascular changes, by means of an in vivo 
imaging approach, across the different LHON stages.
Chronic 
LHON 
patients DOA patients
Control 
group
Chronic LHON 
patients vs 
Control group
DOA patients 
vs Control 
group
Chronic LHON 
patients vs DOA 
patients
Average macular choroidal thickness (μm) 259.8 ± 67.9 250.9 ± 83.4 309.5 ± 38.2 p = 0.002** p < 0.0001** p = 1.0
Macular choroidal SF thickness (μm) 274.9 ± 77.3 254.4 ± 85.2 344.1 ± 49.1 p < 0.0001** p < 0.0001** p = 0.618
Macular choroidal 1500 mμ N thickness (μm) 217.4 ± 73.0 212.9 ± 95.8 256.6 ± 59.2 p = 0.084 p = 0.032* p = 1.0
Macular choroidal 750 mμ N thickness (μm) 252.4 ± 76.8 237.0 ± 85.9 309.2 ± 57.4 p = 0.030* p < 0.0001** p = 1.0
Macular choroidal 1500 mμ S thickness (μm) 260.5 ± 71.3 268.9 ± 79.5 317.6 ± 42.9 p = 0.001** p = 0.003** p = 1.0
Macular choroidal 750 mμ S thickness (μm) 262.8 ± 77.4 261.6 ± 80.81 318.2 ± 44.2 p = 0.002** p = 0.001** p = 1.0
Macular choroidal 1500 mμ T thickness (μm) 257.3 ± 70.5 254.9 ± 80.6 300.1 ± 51.3 p = 0.020* p = 0.008* p = 1.0
Macular choroidal 750 mμ T thickness (μm) 270.4 ± 73.4 257.1 ± 82.6 322.3 ± 44.3 p = 0.030* p < 0.0001** p = 1.0
Macular choroidal 1500 mμ I thickness (μm) 274.3 ± 69.4 260.4 ± 80.5 303.9 ± 40.3 p = 0.143 p = 0.008** p = 1.0
Macular choroidal 750 mμ I thickness (μm) 267.9 ± 68.2 255.8 ± 83.4 313.4 ± 43.7 p = 0.001** p = 0.015* p = 1.0
Average nerve choroidal thickness (μm) 157.4 ± 61.0 144.8 ± 61.0 167.9 ± 37.5 p = 1.0 p = 0.160 p = 0.874
Nerve choroidal T thickness (μm) 165.1 ± 70.0 147.6 ± 72.5 180.1 ± 37.9 p = 0.918 p = 0.070 p = 0.689
Nerve choroidal S thickness (μm) 172.8 ± 71.0 158.2 ± 66.5 182.3 ± 48.2 p = 1.0 p = 0.291 p = 0.940
Nerve choroidal N thickness (μm) 156.5 ± 69.9 150.7 ± 51.7 175.2 ± 51.3 p = 0.521 p = 0.177 p = 1.0
Nerve choroidal I thickness (μm) 135.2 ± 56.8 123.0 ± 52.9 133.3 ± 41.0 p = 1.0 p = 1.0 p = 0.900
Table 3.  Comparison of macular and nerve choroidal thickness among chronic LHON patients, DOA 
patients and the control group. LHON: Leber Hereditary Optic Neuropathy; DOA: Dominant Optic Atrophy; 
SF: sub-foveal; T: temporal quadrant; S: superior quadrant; N: nasal quadrant; I: inferior quadrant. Data are 
showed as mean ± SD. Values were compared between each LHON group and healthy subjects, by means of 
one-way analysis of covariance (ANCOVA), followed by Bonferroni post hoc test. Gender was used as covariate 
in the analysis. *< 0.05, **< 0.01.
Acute 
LHON 
patients
Carrier 
LHON 
patients
Control 
group
Acute LHON 
patients vs 
Control group
Carrier LHON 
patients vs 
Control group
Acute LHON 
patients vs Carrier 
LHON patients
RNFL Average thickness (μm) 121.7 ± 33.1 109.7 ± 10.1 99.9 ± 6.6 p = 0.002** p = 0.038* p = 0.001**
RNFL T thickness (μm) 64.7 ± 19.3 83.4 ± 15.3 67.38 ± 10.6 p = 1.0 p < 0.0001** p = 0.001**
RNFL S thickness (μm) 169.9 ± 33.4 131.5 ± 14.6 129.3 ± 16.1 p < 0.0001** p = 1.0 p < 0.0001**
RNFL N thickness (μm) 95.2 ± 13.5 82.7 ± 20.1 79.0 ± 16.6 p = 0.061 p = 1.0 p = 0.190
RNFL I thickness (μm) 158.1 ± 16.4 144.1 ± 20.5 123.7 ± 10.6 p < 0.0001** p < 0.0001** p = 0.018*
Table 4.  Comparison of Retinal Nerve Fiber Layer thickness between LHON patients and the control 
group. LHON: Leber Hereditary Optic Neuropathy; RNFL: Retinal Nerve Fiber Layer; SF: sub-foveal; 
T: temporal quadrant; S: superior quadrant; N: nasal quadrant; I: inferior quadrant. Data are showed as 
mean ± SD. Values were compared between each LHON group and healthy subjects, by means of one-way 
analysis of covariance (ANCOVA), followed by Bonferroni post hoc test. Gender was used as covariate in the 
analysis. *< 0.05, **< 0.01.
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Our group recently reported postmortem evidence of vessel involvement in LHON26. Indeed, we demon-
strated mitochondrial proliferation affecting both the endothelial and the smooth muscle components of blood 
vessel walls in LHON patients26. Mitochondrial proliferation is part of a thickening of the vessel wall, an increase 
in the vessel size, as well as a decrease in the lumen diameter, which we have defined as a mitochondrial angi-
opathy. This finding resembles the hallmark features of mitochondrial encephalomyopathy, lactic acidosis, 
stroke-like episodes (MELAS) syndrome, and we proposed that in the acute phase of LHON there may be a sim-
ilar stroke-like episode occurring at the metabolically susceptible optic nerve head.
Taking into account these considerations, the choroidal thickening seen during the LHON acute phase may 
be part of a compensatory response. Vessels in the choroid may simply be more numerous and or wider, as would 
happen in response to angiogenic factors (vascular endothelial growth factor–VEGF being just one of the many 
trophic factors). Such exuberance of vessels is often in consequence to ischemia stimulating hypoxia inducible 
factor 1-alpha (HIF-1) that in turn causes downstream upregulation of VEGF and other growth factors. HIF-1 
is upregulated under conditions of hypoxia27, but also through a redox-sensitive mechanism and by reactive 
oxygen species (ROS)28. These conditions of “pseudo-hypoxia” may likely characterize the acute phase of LHON. 
Finally, increased heat production, secondary to the high metabolic rate and partially uncoupled mitochondrial 
oxidative phosphorylation due to a complex I defect in LHON, may further aggravate the situation27–29. Recently, 
it has been provided evidence that complex I deficiency may signal a pseudohypoxic state in susceptible tissues 
such as the RGCs and RNFL30. These effects may be additive and not mutually exclusive. Moreover, interestingly, 
the choroid was found thicker also in carrier patients, but only in the inferior peri-optic nerve sector. The latter 
aspect could be explained by the fact that the peripapillary inferior quadrant is thinner than the other quadrants 
in healthy patients, as shown by several studies31,32, and this thinning could have been missed in patients carrying 
LHON mutations.
The natural history of peripapillary RNFL changes throughout the different LHON phases has been quantita-
tively described8,18,19. Our study confirmed a thickening occurring in RNFL layer inferior-temporally, in LHON 
mutation carriers. The RNFL swelling is likely to depend on the compensatory increase of mitochondrial bio-
genesis and/or axonal stasis along the fibers. Moreover, we found RNFL temporal thinning in the LHON acute 
phase, affecting initially the papillomacular bundle. The latter aspect is well described in the acute LHON group, 
Chronic 
LHON 
patients
DOA 
patients
Control 
group
Chronic LHON 
patients vs 
Control group
DOA patients 
vs Control 
group
Chronic LHON 
patients vs 
DOA patients
RNFL Average thickness (μm) 46.7 ± 11.6 58.6 ± 9.1 99.9 ± 6.6 p < 0.0001** p < 0.0001** p < 0.0001**
RNFL T thickness (μm) 29.5 ± 15.2 27.6 ± 7.6 67.38 ± 10.6 p < 0.0001** p < 0.0001** p = 1.0
RNFL S thickness (μm) 62.5 ± 17.2 83.9 ± 13.9 129.3 ± 16.1 p < 0.0001** p < 0.0001** p < 0.0001**
RNFL N thickness (μm) 38.6 ± 17.9 51.2 ± 11.5 79.0 ± 16.6 p < 0.0001** p < 0.0001** p = 0.002**
RNFL I thickness (μm) 56.5 ± 11.7 71.8 ± 14.9 123.7 ± 10.6 p < 0.0001** p < 0.0001** p < 0.0001**
Table 5.  Comparison of Retinal Nerve Fiber Layer thickness among chronic LHON patients, DOA patients 
and the control group. LHON: Leber Hereditary Optic Neuropathy; DOA: Dominant Optic Atrophy; RNFL: 
Retinal Nerve Fiber Layer; SF: sub-foveal; T: temporal quadrant; S: superior quadrant; N: nasal quadrant; I: 
inferior quadrant. Data are showed as mean ± SD. Values were compared between each LHON group and 
healthy subjects, by means of one-way analysis of covariance (ANCOVA), followed by Bonferroni post hoc test. 
Gender was used as covariate in the analysis. *< 0.05, **< 0.01.
Figure 2. Boxplot of average retinal nerve fiber layer (RNFL), macular and nerve choroid (left panel) 
thickness, and of temporal RNFL, temporal and nasal macular choroid, and temporal nerve choroid (right 
panel) thickness in all groups. 
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indeed these patients were not tested only at disease onset, but three months later. Finally, the entire RNFL layer 
was reduced in chronic LHON patients, as well as in DOA subjects.
Despite the cross-sectional nature of our study, the direct correlation between RNFL and choroidal thick-
nesses at the different disease stages suggested that the changes occurring at these two structures are related. The 
increase of RFNL thickness preceded the increase of choroid thickness, both in the macula and peripapillary 
regions, strongly suggesting that one event may drive the other.
We also showed that choroid and RNFL thickness were both reduced in C-LHON and DOA patients. 
Interestingly, the RNFL was thinner in LHON as compared to DOA, whereas the choroid thickness followed an 
opposite trend being thicker in LHON than DOA. We propose that in LHON, a low-rate ongoing axonal degener-
ation as shown at histopathology1,3,26, maintains the signaling for blood vessels to prolong the choroidal changes. 
We also speculate that in DOA patients, for which RGC and axonal loss occurs over decades, there is a reduction 
in the overall metabolic rate of the retina accompanied by a corresponding reduction of choroidal thickness. 
Indeed, there was a direct correlation between RNFL and choroidal thickness.
Limitations of the present study include the cross-sectional nature of the study design. However considering 
the rarity of LHON, the transition from the asympthomatic to the acute stage is particularly difficult to observe 
and follow longitudinally. Furthermore, to substantiate the hypothesis of a pseudo-hypoxic tissue condition, pro-
moting the choroidal and vessel changes through the angiogenic signaling, will need specific investigation, both 
in vitro and histopathology level. To this end it might be also instrumental to investigate the now available LHON 
mouse model33. Another limitation is that we did not measure the axial length, which was shown to influence the 
choroid measurements34. However, it should be considered the low variability of refractive error in the enrolled 
subjects and no patient underwent refractive surgery, thus minimizing the possible influence of axial length on 
choroidal thickness. Finally, we did not assess test-retest variability in choroidal measurement. Nevertheless, cho-
roidal measurements were shown to have a high intra-observer and interobserver reproducibility35.
In conclusion, we provide the first quantitative assessment of choroidal thickness in LHON, as compared to 
controls and DOA, and we substantiate the involvement of choroidal vessels in correlation to the RNFL changes 
during the different stages of LHON. The increase in choroidal thickness is a feature of the LHON acute stage, 
which may follow the pathological events occurring at the RGC and axonal level. Conversely, thinning of the 
Figure 3. Retinal nerve fiber layer (RNFL) and choroid thickness change in the LHON subjects, stratified 
into asymptomatic carriers, acute, dynamic and chronic stages. Solid lines indicate average measurements of 
RNFL, nerve and macular choroid thicknesses, whereas dotted lines indicate measurements corresponding to 
the papillomacular bundle region, in particular temporal RNFL, nerve choroid temporal and macular choroid 
nasal thicknesses. Changes are reported as percentage of change from the average value of healthy controls.
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choroidal layer is the common outcome in the chronic stage of LHON and in DOA. Choroid thickness in chronic 
LHON exceeds that in DOA, possibly as consequence of the still ongoing insidious metabolic neurodegeneration 
in LHON. Choroidal measures may become a new useful tool to monitor disease activity and efficacy of new 
therapeutic approaches. We also envisage that the vascular changes occurring in LHON during the acute stage 
may become a therapeutic target, once their role in LHON pathogenesis is further clarified.
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